Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$10.28MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Marshall Fordyce
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 362
- Beta
- 0.95
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 4.06
Financials
Revenue
$10.28M+0.0%Net Income
$-93.71MEBITDA
$-91.02MFree Cash Flow
$-99.18MEPS (diluted)
$-1.30Shares Outstanding (diluted)
72.13M+1669.4%Operating Expenses
$102.68MCash & Debt
$384.04MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-299.62M | $-4.66 |
| 2024 | $0.00 | $-152.15M | $-2.75 |
| 2023 | $0.00 | $-95.99M | $-2.25 |
| 2022 | $0.00 | $-89.06M | $-3.35 |
| 2021 | $0.00 | $-32.61M | $-2.43 |
| 2020 | $0.00 | $-53.41M | $-14.40 |
| 2019 | $0.00 | $-11.85M | $-3.46 |
Valuation
VERAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (13)
- Newsmarketbeat.com·16d ago·Neutral
Vera Therapeutics Q3 Earnings Call Highlights Vera Therapeutics NASDAQ: VERA reported $10.3 million in third-quarter TRUTAKNA sales, its first partial quarter of commercial revenue, as the company pursues full U.S. approval for the kidney disease treatment.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Vera Therapeutics, Inc. (VERA) Q3 2026 Earnings Call Transcript Vera Therapeutics, Inc. (VERA) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·17d ago·Negative
Vera Therapeutics, Inc. (VERA) Reports Q3 Loss, Tops Revenue Estimates Vera Therapeutics, Inc. (VERA) came out with a quarterly loss of $1.3 per share versus the Zacks Consensus Estimate of a loss of $1.72. This compares to a loss of $1.26 per share a year ago.
View source ↗ - Newsmarketbeat.com·31d ago·Positive
Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results Vera Therapeutics NASDAQ: VERA reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept, marketed as TRUTAKNA, in adults with IgA nephropathy. The company presented the data at the American Society of Nephrology's Kidney Week meeting in Denver, alongside publication in The New England Journal of Medicine.
View source ↗ - Newsseekingalpha.com·31d ago·Positive
Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript
View source ↗ - Newsglobenewswire.com·31d ago·Positive
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk reduction in composite kidney disease progression events. Favorable safety profile, and genera
View source ↗ - Newsglobenewswire.com·51d ago·Neutral
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgAN Will be A Featured Late-breaking Oral Presentation at Opening Plenary of ASN 2026
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsbarrons.com·68d ago·Negative
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.
View source ↗ - Newsinvezz.com·68d ago·Positive
Why is Vera Therapeutics stock reversing its premarket gains? Vera Therapeutics (VERA) shares ripped higher in premarket trading on September 15 as investors reacted to landmark clinical data. The biopharmaceutical firm announced that its lead therapy TRUTAKNA (atacicept-vymj) met all primary and secondary endpoints in the final 104-week efficacy analysis of its Phase 3 ORIGIN 3 trial for primary IgA nephropathy (IgAN).
View source ↗ - Newsschaeffersresearch.com·68d ago·Negative
Vera Stock Slides Despite Positive Phase 3 Results Vera Therapeutics (NASDAQ:VERA) stock is down 2% to trade at $33.34, reversing earlier gains after disclosing positive late-stage ORIGIN 3 trial results for the company's TRUTAKNA drug.
View source ↗ - Newsglobenewswire.com·82d ago·Neutral
Vera Therapeutics to Participate at Upcoming Investor Conferences BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.
View source ↗ - Newsseekingalpha.com·97d ago·Positive
Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy Vera Therapeutics is upgraded to Buy following TRUTAKNA's FDA approval and encouraging eGFR data. The FDA's exploratory eGFR analysis shows stable kidney function with TRUTAKNA, supporting the bull case ahead of full phase 3 data in Q3 2026. TRUTAKNA faces competition from Otsuka's VOYXACT and Vertex's povetacicept but enjoys a commercial head start and broad label.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-1.46 per share
Typical surprise -4.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-1.30 vs $-1.62beat
- Mon, Aug 10$-1.52 vs $-1.58beat
- Thu, May 7$-1.69 vs $-1.33miss
- Thu, Feb 26$-1.39 vs $-1.34miss
- Wed, Nov 5$-1.26 vs $-1.20miss
- Tue, Aug 5$-1.20 vs $-0.82miss
Estimates and results for VERA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VERA officers and directors.
- Bought
- $5.5m
- Sold
- $12.3m
5 trades
33 trades
- Fordyce Marshallsold
- Fordyce Marshallsold
- Fordyce Marshallsold
- Fordyce Marshallsold
- Fordyce Marshallsold
- Fordyce Marshallsold
- Fordyce Marshallsold
- Fordyce Marshallsold
62 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VERA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
